Why would a provider deny Mounjaro?

If you’re exploring weight loss treatment options and wondering whether you can access medications like Wegovy, Ozempic, or Mounjaro through telehealth, you’re not alone. Millions of Americans are now turning to virtual healthcare for obesity management—and the short answer is yes, you can legally get GLP-1 weight loss medications through telehealth in most of the United States.

But there’s more to the story. While federal law broadly permits telehealth prescribing of these medications, state regulations vary significantly. Some states require an initial in-person visit, while others allow you to complete your entire weight loss journey virtually. This comprehensive guide breaks down everything you need to know about accessing weight loss medications through telehealth in 2025, including state-specific rules, provider qualifications, and what to expect during your virtual consultation.

Understanding the Federal Framework for Telehealth Weight Loss Prescriptions

The good news for patients seeking weight loss treatment: GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances under federal law. This means they’re not subject to the Ryan Haight Act’s strict in-person examination requirement that applies to medications like Adderall or opioids.

During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) temporarily waived many telehealth restrictions to ensure patients could access care safely from home. These flexibilities have been extended multiple times—most recently through December 31, 2025—but they primarily affect controlled medications. For weight loss drugs, the regulatory landscape has been more straightforward: if you can establish a valid patient-provider relationship via telehealth, your provider can prescribe these medications electronically.

What Changed After the Pandemic?

While pandemic-era emergency measures relaxed many healthcare rules temporarily, the transition back to ‘normal’ has been gradual and thoughtful. The DEA and HHS announced in November 2024 that telehealth prescribing flexibilities would continue through the end of 2025, with expectations of further extensions or permanent rules in 2026. This signals federal support for expanded telehealth access—especially for treatments like obesity management that benefit from ongoing virtual monitoring.

For patients, this means telehealth weight loss programs aren’t going anywhere. In fact, they’re becoming more established as states update their medical practice acts to align with modern healthcare delivery.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Rules: Where Can You Get Virtual Weight Loss Treatment?

While federal law sets the baseline, state medical boards determine the specific requirements for prescribing weight loss medications via telehealth. Here’s what you need to know about the major variations:

States with Full Telehealth Access (No In-Person Visit Required)

Several states allow healthcare providers to prescribe weight loss medications entirely through telehealth after establishing a valid patient relationship via video consultation:

California leads the way with robust telehealth infrastructure and no mandatory in-person examination. Nurse practitioners in California can practice independently after gaining experience, making virtual weight loss care widely accessible.

Washington State has been a pioneer in telehealth adoption, with no restrictions on virtual prescribing of GLP-1 medications. The state’s advanced privacy laws also ensure your sensitive health information remains protected.

New York permits full telehealth evaluation and prescribing, with NPs enjoying independent practice authority. The state’s mandatory electronic prescribing requirements actually make telehealth prescriptions more streamlined.

Connecticut allows comprehensive virtual care but requires providers to include behavioral counseling and documented diet/exercise plans as part of obesity treatment—a standard that actually benefits patients by ensuring holistic care.

Illinois and Pennsylvania similarly permit telehealth prescribing without in-person mandates, though Pennsylvania requires NPs to maintain physician collaboration agreements.

States Requiring Initial In-Person Evaluations

Some states maintain traditional medical standards that require at least one face-to-face encounter before or shortly after starting telehealth weight loss treatment:

Arkansas has some of the strictest telehealth regulations in the nation, requiring an initial in-person physical examination before prescribing can begin via telehealth. While this adds a step, it ensures thorough baseline assessment.

Georgia similarly mandates an in-person exam prior to telehealth prescribing. However, a significant 2024 law expanded NP and PA prescribing authority, making it easier to find qualified providers.

Texas generally expects an initial in-person evaluation consistent with the standard of care for obesity treatment. Texas has particularly stringent oversight of telehealth weight loss clinics, requiring NPs and PAs to work under formal physician agreements.

Delaware, Mississippi, New Jersey, North Dakota, and South Carolina all require initial in-person physical examinations before providers can manage your weight loss treatment virtually.

States with Special Requirements

Florida takes a unique approach: no in-person visit is strictly required, but state law mandates that patients have a BMI of 30 or higher (or 27+ with comorbidities) and must be seen—either in person or virtually—at least once every three months during treatment.

Virginia requires a comprehensive initial work-up including physical exam, laboratory testing, and a personalized diet and exercise plan, with mandatory follow-up within 30 days of starting medication.

New Jersey has similar requirements, mandating extensive baseline evaluation with labs, psychological screening, and documentation of risks before prescribing weight loss medications.

Who Can Prescribe Weight Loss Medications Through Telehealth?

Understanding provider qualifications helps you know what to expect during your virtual consultation.

Physicians (MDs and DOs)

All licensed physicians can prescribe GLP-1 weight loss medications via telehealth in any state where they hold an active medical license. When you connect with a telehealth platform, you’ll likely be matched with a physician licensed in your state of residence.

Nurse Practitioners (NPs)

Nurse practitioners represent a growing portion of telehealth weight loss providers, but their prescribing authority varies significantly by state:

• Independent Practice States (34 states plus DC as of 2025): NPs can evaluate, diagnose, and prescribe weight loss medications without physician oversight. These include California, Washington, New York, Arizona, Connecticut, and Utah.

• Collaborative Practice States: NPs must maintain agreements with supervising physicians but can still provide comprehensive care. Examples include Florida, Pennsylvania, Illinois, and Georgia.

• Restricted States: A handful of states impose significant limitations on NP prescribing. Texas, for instance, requires formal delegation agreements and prohibits NPs from prescribing certain controlled substances (though GLP-1 medications are permitted).

Physician Assistants (PAs)

PAs can prescribe weight loss medications in all states but generally require a collaborative or supervisory relationship with a physician. The specifics vary: some states allow PAs considerable autonomy, while others mandate closer oversight.

What to Expect During Your Telehealth Weight Loss Consultation

Reputable telehealth providers follow rigorous clinical protocols to ensure patient safety and treatment effectiveness. Here’s what a legitimate virtual weight loss consultation looks like:

Initial Assessment

Your first step typically involves completing a comprehensive medical questionnaire covering:

• Current height, weight, and BMI calculation
• Complete medical history including cardiovascular, gastrointestinal, and endocrine conditions
• Current medications and supplements
• History of weight loss attempts and lifestyle factors
• Family history of thyroid cancer or Multiple Endocrine Neoplasia syndrome (critical screening for GLP-1 safety)
• Mental health history and eating disorder screening
• Goals and expectations for treatment

Live Video Consultation

Unlike questionable online pharmacies that may approve prescriptions based solely on a questionnaire, legitimate telehealth platforms require a live video consultation with a licensed healthcare provider. During this visit, your provider will:

• Review your medical history in detail
• Discuss treatment options and set realistic expectations
• Explain potential side effects and contraindications
• Verify your eligibility based on BMI and medical criteria
• Create a personalized treatment plan including lifestyle modifications
• Obtain informed consent documenting your understanding of risks and benefits

Laboratory Testing

Many providers require recent lab work before prescribing weight loss medications, including:

• Comprehensive metabolic panel (kidney and liver function)
• Lipid panel
• Hemoglobin A1C (for diabetes screening)
• Thyroid function tests
• Complete blood count

Some states (like New Jersey and Virginia) legally mandate these tests; even where not required, responsible providers order them as part of best practices.

Ongoing Monitoring

Weight loss medication isn’t a one-time prescription. Expect regular follow-up visits—typically monthly at first, then every 2-3 months once your dose is stable. These check-ins allow your provider to:

• Monitor weight loss progress
• Assess and manage side effects
• Adjust medication dosage as needed
• Reinforce lifestyle modifications
• Order periodic lab work to ensure safety

Florida and Virginia explicitly require these follow-ups by law, but any reputable telehealth provider will build them into your treatment plan.

Clinical Criteria: Who Qualifies for Weight Loss Medications?

GLP-1 medications are powerful tools, but they’re intended for patients with medical need, not cosmetic weight loss. Standard eligibility criteria include:

BMI Requirements:

• BMI ≥ 30 (classified as obese), OR
• BMI ≥ 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea

Medical Appropriateness:Patients must not have contraindications including:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or plans to become pregnant (must discontinue 2 months before conception)
• History of severe pancreatitis
• Active gallbladder disease
• Severe gastroparesis or gastrointestinal disorders
• Uncontrolled mental health conditions or active eating disorders

Lifestyle Commitment:Most states require documentation that patients understand weight loss medication works best alongside diet and exercise modifications. Providers will discuss nutrition, physical activity goals, and behavioral strategies as part of your treatment plan.

Understanding Your Medication Options

Three GLP-1 medications dominate the telehealth weight loss landscape:

Wegovy (Semaglutide 2.4mg)

FDA-approved specifically for chronic weight management in adults with obesity or overweight with comorbidities. Wegovy is administered as a once-weekly subcutaneous injection, with gradual dose escalation over 16-20 weeks.

What to expect: Clinical trials showed average weight loss of 15-20% of body weight over 68 weeks when combined with lifestyle interventions. Common side effects include nausea, diarrhea, constipation, and potential gallstone formation.

Insurance and cost: Some insurance plans cover Wegovy for weight loss (unlike Ozempic used off-label), but coverage varies. Cash prices typically range $1,200-$1,400 per month, though telehealth platforms often negotiate better rates.

Ozempic (Semaglutide 0.5-1mg)

FDA-approved for type 2 diabetes, Ozempic is frequently prescribed off-label for weight loss. It contains the same active ingredient as Wegovy but in different dosing.

Off-label considerations: While legal and common, off-label prescribing requires clear documentation of medical rationale and informed consent. Responsible telehealth providers will explain that you’re receiving the medication for an unapproved use.

Insurance and cost: More likely to be covered if you have diabetes or prediabetes. Off-label use for weight loss alone typically isn’t covered, leaving patients to pay out-of-pocket.

Mounjaro (Tirzepatide)

Originally approved for type 2 diabetes, tirzepatide targets both GLP-1 and GIP receptors, potentially offering greater weight loss efficacy. The FDA approved a dedicated weight loss formulation called Zepbound in late 2023.

Clinical promise: Studies show average weight loss of 20-25% of body weight—surpassing semaglutide in head-to-head trials.

Current status: Increasingly available through telehealth for both diabetes management and (under the Zepbound branding) obesity treatment.

The Compounded Medication Question: What You Need to Know

Until recently, some telehealth companies offered ‘compounded’ versions of semaglutide—custom-made formulations prepared by specialty pharmacies rather than brand-name Wegovy or Ozempic. These were often marketed at much lower prices.

Major regulatory change in 2025: The FDA officially ended the drug shortage designation for semaglutide and effectively banned routine compounding of these medications effective May 2025. This decision followed safety concerns about compounded formulations that may not match the quality, purity, or efficacy of FDA-approved products.

What this means for patients: If a telehealth provider offers ‘compounded semaglutide’ or suspiciously cheap GLP-1 options, be cautious. Legitimate compounding is now restricted to very limited circumstances (such as patients with documented allergies to inactive ingredients in brand formulations).

Bottom line: Stick with FDA-approved medications dispensed through licensed pharmacies. While more expensive upfront, you’re guaranteed pharmaceutical-grade medication with proven safety profiles.

Red Flags: How to Spot Questionable Telehealth Weight Loss Services

The popularity of GLP-1 medications has attracted both legitimate healthcare providers and concerning opportunists. Protect yourself by watching for these warning signs:

Guarantee of Prescription

Any service that promises you’ll receive a prescription before you’ve even completed an evaluation is prioritizing profits over patient safety. Legitimate providers assess eligibility carefully and may determine you’re not an appropriate candidate.

No Live Video Consultation

While asynchronous telehealth (questionnaire-only) is legal in some contexts, responsible obesity treatment requires a live, interactive video visit with a licensed provider. If a service never schedules a video call, reconsider.

Compounded or International Medications

As discussed above, offers of ‘affordable’ compounded semaglutide or medications sourced from overseas pharmacies raise serious red flags. These products may be counterfeit, contaminated, or improperly stored.

Lack of Follow-Up Care

Weight loss medications require ongoing monitoring. Services that prescribe and disappear aren’t providing adequate medical care and may be operating in violation of state medical practice standards.

Unclear Provider Credentials

You should be able to easily verify your provider’s license, credentials, and the state(s) where they’re authorized to practice. If the platform won’t tell you who your prescriber is or seems evasive about licensing, that’s a major concern.

Unrealistic Promises

Claims like ‘Lose 30 pounds in 30 days!’ or ‘Get skinny fast with no side effects!’ are marketing, not medicine. Responsible providers set realistic expectations: gradual weight loss of 1-2 pounds per week, potential side effects that need management, and the necessity of lifestyle changes.

How Klarity Health Approaches Telehealth Weight Loss Care

At Klarity Health, we’ve built our weight loss program around the principle that access and quality aren’t mutually exclusive. Our approach ensures you receive evidence-based care while enjoying the convenience of telehealth:

Provider Availability: We maintain a network of board-certified physicians and experienced nurse practitioners licensed across multiple states, so you can typically schedule a consultation within 24-48 hours rather than waiting weeks for an in-person appointment.

Transparent Pricing: We accept most major insurance plans and also offer clear cash-pay pricing for patients whose insurance doesn’t cover weight loss treatment. There are no surprise bills or hidden fees—you’ll know your cost upfront.

Comprehensive Care Model: Our providers don’t just write prescriptions. Your treatment plan includes nutritional guidance, exercise recommendations, behavioral coaching resources, and regular check-ins to monitor progress and adjust your approach as needed.

State Compliance: We ensure every consultation meets or exceeds your state’s specific telehealth requirements. If you’re in a state requiring an initial in-person exam, we’ll help coordinate that through our partner network before beginning telehealth management.

Quality Medications: We only prescribe FDA-approved brand-name medications (Wegovy, Ozempic, Mounjaro/Zepbound) dispensed through vetted partner pharmacies. We don’t work with compounding pharmacies or overseas suppliers.

Practical Steps: How to Start Your Telehealth Weight Loss Journey

If you’re ready to explore telehealth weight loss treatment, here’s how to proceed:

1. Verify Your Eligibility

Calculate your BMI and assess whether you meet the clinical criteria. If you’re borderline or unsure, that’s okay—your provider will make the final determination during your consultation.

2. Research State-Specific Requirements

Check the state-by-state table in this guide to understand whether you’ll need an initial in-person visit or can complete everything virtually. This helps you set realistic expectations.

3. Choose a Reputable Telehealth Platform

Look for services with clear provider credentials, live video consultations, transparent pricing, and comprehensive care models. Platforms affiliated with established healthcare organizations tend to offer more robust oversight.

4. Gather Your Medical Information

Before your consultation, compile:

• List of current medications and supplements
• Recent lab results if available
• Summary of previous weight loss attempts
• Any relevant medical records (diabetes diagnosis, cardiovascular history, etc.)

5. Prepare Questions for Your Provider

Come ready to discuss:

• Which medication might be best for your situation
• Expected timeline for results
• How to manage potential side effects
• Insurance coverage and out-of-pocket costs
• Follow-up schedule and monitoring plan

6. Commit to the Process

GLP-1 medications are tools, not magic bullets. Success requires consistent use, regular follow-up, and genuine effort with nutrition and physical activity. Patients who embrace the comprehensive approach see the best long-term results.

Insurance Coverage and Cost Considerations

One of the most common questions: ‘Will my insurance cover this?’

Coverage varies significantly:

• Medicare: Currently doesn’t cover weight loss medications (a policy many advocates are working to change)
• Medicaid: Coverage depends on your state; some states cover obesity treatment, others don’t
• Private Insurance: Increasingly covers FDA-approved weight loss medications like Wegovy, but often with restrictions (step therapy requiring diet/exercise programs first, prior authorization, BMI minimums)

Telehealth visits are typically covered by insurance on par with in-person consultations, thanks to pandemic-era policy changes that have been extended in most states.

Cash-pay options: If insurance doesn’t cover your treatment, telehealth platforms often offer more affordable rates than traditional medical practices. Monthly medication costs typically range from $250-$350 through programs negotiated by telehealth providers, compared to $1,200-$1,400 retail price.

Some manufacturers offer patient assistance programs that can significantly reduce costs if you qualify based on income.

What the Future Holds: Regulatory Trends for 2026 and Beyond

The telehealth landscape continues to evolve. Here’s what’s on the horizon:

Federal Legislation: The bipartisan TREATS Act, reintroduced in October 2025, would make permanent many telehealth prescribing flexibilities currently operating under temporary extensions. While focused primarily on addiction treatment and mental health medications, passage would signal broad congressional support for expanded telehealth access.

State Practice Authority Expansion: Expect more states to grant nurse practitioners full practice authority. Mississippi, Pennsylvania, and several others have pending legislation that would allow NPs to practice independently, expanding the telehealth provider pool.

Continued DEA Extensions: The current telehealth flexibilities for controlled substances expire December 31, 2025, but the DEA has signaled another extension is likely as they continue crafting permanent regulations. This doesn’t directly affect GLP-1 medications but indicates general regulatory support for telehealth.

New Obesity Medications: Several promising weight loss drugs are in late-stage clinical trials. As these enter the market, expect telehealth platforms to offer additional options beyond current GLP-1 medications.

Tighter Compounding Oversight: Following the 2025 FDA ban on compounded semaglutide, expect stricter enforcement against pharmacies attempting workarounds and continued scrutiny of any ‘alternative’ formulations.

Moving Forward: Making Informed Decisions About Your Weight Loss Treatment

The ability to access weight loss medications through telehealth represents a significant advancement in obesity care. For many patients, virtual treatment removes barriers that prevented them from seeking help—whether that’s limited local provider availability, stigma around discussing weight in person, scheduling challenges, or simple convenience.

But with expanded access comes responsibility: yours to research options carefully and choose reputable providers, and the healthcare system’s to maintain rigorous standards despite the virtual format.

The bottom line: Yes, you can get weight loss medications through telehealth safely and legally in most states. The key is connecting with providers who prioritize comprehensive care over quick prescriptions, who operate transparently within regulatory guidelines, and who see you as a partner in your health journey rather than a transaction.

Whether you’re just beginning to explore weight loss treatment or you’ve tried other approaches without success, telehealth offers a viable path forward. Take the time to understand your state’s specific requirements, verify you’re working with licensed professionals, and commit to the full treatment process—not just the medication, but the lifestyle changes that create lasting results.

Your health journey is unique to you, but you don’t have to navigate it alone. Modern telehealth platforms make it easier than ever to access expert guidance, evidence-based treatment, and ongoing support from the comfort of home.

Frequently Asked Questions

Is telehealth weight loss treatment as effective as in-person care?

Research consistently shows telehealth obesity treatment produces comparable outcomes to traditional in-person care when protocols include video consultations, regular monitoring, and comprehensive lifestyle support. The convenience of telehealth may actually improve adherence for many patients.

Can I use my FSA or HSA to pay for telehealth weight loss treatment?

Yes, both consultations and FDA-approved weight loss medications generally qualify as eligible medical expenses for Flexible Spending Accounts and Health Savings Accounts. Check with your plan administrator for specific guidance.

What happens if I move to a different state during treatment?

You’ll need to transition to a provider licensed in your new state. Many multi-state telehealth platforms can facilitate this seamlessly by connecting you with a provider in your new location who can review your records and continue your care.

How long will I need to take weight loss medication?

GLP-1 medications are intended for chronic weight management—meaning potentially indefinite use, similar to how diabetes or high blood pressure medications are taken long-term. Clinical trials show patients typically regain weight if they discontinue medication, so most people continue treatment as long as they’re seeing benefits and tolerating it well.

Are there age restrictions for telehealth weight loss treatment?

Most providers treat adults ages 18-65. Some may treat patients 16-17 with parental consent if they meet clinical criteria. Adults over 65 may be candidates but require more careful evaluation given higher risk of age-related complications.

Sources and References

Research Currency Statement
Verified as of: December 17, 2025

All information in this article reflects current regulations as of December 2025. Federal telehealth rules for controlled substances are temporary through December 31, 2025, with extensions expected. State laws continue to evolve; readers should verify current regulations in their state before beginning treatment.

Top 5 Primary Sources:

1. Drug Enforcement Administration (DEA) Official Announcement – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024). Retrieved from www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Axios News – ‘COVID-era telehealth prescribing extended’ (November 18, 2024). Retrieved from www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. McDermott Will & Emery Law Firm – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (November 18, 2024). Retrieved from www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025

4. Goodwin Procter Law Firm – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 27, 2024). Retrieved from www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. Reuters – ‘Hims & Hers cuts 4% of workforce amid ban on weight-loss drug copies’ (May 30, 2025). Retrieved from www.reuters.com/business/healthcare-pharmaceuticals/hims-cut-4-workforce-amid-ban-weight-loss-drug-copies-2025-05-30

Additional authoritative sources consulted include: Nextech state-by-state regulatory analysis (April 2025), Texas Medical Board prescribing guidance, U.S. Senate press releases regarding the TREATS Act (October 2025), National Law Review telehealth compliance articles, and state medical board regulations from Arkansas, California, Connecticut, Delaware, Florida, Georgia, Illinois, Mississippi, New Jersey, New York, North Dakota, Pennsylvania, South Carolina, Texas, Utah, Virginia, and Washington.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid